Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jessica Merrill

New York, NY
Jessica Merrill is a Bureau Editor for US Commercial Content for Informa’s pharmaceutical news publications, including “The Pink Sheet” and SCRIP. She has been covering the pharmaceutical industry as a journalist for more than 10 years, spanning the spectrum from R&D to regulatory to commercial. She was previously a reporter and editor for “The Pink Sheet” and “Pink Sheet” DAILY, specializing in business and commercial news, focusing largely on big pharma, M&A and business development, and the commercial landscape, including drug launches and market access. Before embarking on a career in healthcare journalism, she covered business news for the cosmetics industry and worked as a newspaper reporter.
Advertisement
Set Alert for Articles By Jessica Merrill

Latest From Jessica Merrill

J&J's Erleada Approved By FDA In New Prostate Cancer Indication

Erleada was approved for treatment of metastatic castration-sensitive prostate cancer (mCSPC), strengthening its position versus generic Zytiga and Pfizer/Astellas's Xtandi.

Cancer Approvals

Purdue's Opioid Rescue Drug Development To Continue Under A New Company

Purdue proposes continuing the development of nalmefene hydrochloride and other products under a new company that would provide the products at no or low cost.

Companies Research & Development

Purdue Pharma: From Blockbuster Success To Bankrupt Villain

Purdue's rise and fall through opioids will likely end in bankruptcy, raising new questions around ongoing lawsuits and shining a light on the toll the opioid liability will leave on the industry. 

Legal Issues Companies

Moderna Edges Closer To Becoming A Mid-Stage Drug Development Company

The mRNA specialist outlined ambitious plans to bring a vaccine for cytomegalovirus to market during an R&D day after releasing positive Phase I data.

Research & Development Vaccines

GSK Buys One Of Eight Firms Formed In VC Partnership With Avalon

Celiac disease specialist Sitari was the first company formed under the six-year collaboration. Three were shut down and Avalon controls the other four, which aren't compatible with GSK's new R&D focus.

Deals Financing

Acadia Claims Success For Nuplazid In A Broader Psychosis Indication

The company expects to file pimavanserin for the treatment of dementia-related psychosis in 2020, based on the results of a single positive Phase III trial.

Neurology Clinical Trials
See All
Advertisement
UsernamePublicRestriction

Register